Please login to the form below

Not currently logged in
Email:
Password:

multiple myeloma

This page shows the latest multiple myeloma news and features for those working in and with pharma, biotech and healthcare.

Darzalex powers ahead with frontline myeloma approval in Europe

Darzalex powers ahead with frontline myeloma approval in Europe

Johnson &Johnson’s Darzalex is to take a more central role in multiple myeloma treatment following its European approval in a new frontline combination. ... A rival biologic in multiple myeloma is BMS and AbbVie’s  Empliciti (elotuzumab), though

Latest news

More from news
Approximately 40 fully matching, plus 204 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    ASCO last year, and a larger, 1, 000-patient study across multiple cancers is due to report in 2020. ... The CAR-Ts have transformed the treatment of childhood ALL – an otherwise incurable blood cancer – and have been shown to work in hard-to-treat

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    Its fourth pipeline candidate is the multiple myeloma targeting CAR-T therapy bb2121, being co-developed with Celgene, which is tipped to be Bluebird’s potential blockbuster and therefore most crucial ... This is especially likely around its multiple

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    Among the noteworthy orphan approvals are Exondys 51 (for the treatment of Duchenne muscular dystrophy, only approved in the US), Darzalex (for the treatment of multiple myeloma, approved in the US

  • Deal Watch September 2016 Deal Watch September 2016

    Boehringer Ingelheim granted Amgen worldwide rights to BI 836909, a bispecific T cell engager designed to treat multiple myeloma.

  • Does safety sell medicines? Does safety sell medicines?

    Who would have thought 50 years ago that thalidomide would be back on the UK market helping patients with life-threatening multiple myeloma - possible due to a risk management programme centered

More from intelligence
Approximately 0 fully matching, plus 20 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics